Fri, Oct 31, 2014, 4:11 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amgen, Inc. (AMGN) Message Board

dinepat203 576 posts  |  Last Activity: 1 hour 11 minutes ago Member since: Sep 29, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    2 years ago $20+, now $$5.5+

    by bollingr_band Oct 18, 2014 6:43 PM
    dinepat203 dinepat203 Oct 20, 2014 1:27 PM Flag

    igold is firm sitting above $1245

  • Reply to

    ONLY BCRX is the EBOLA winner ...

    by dinepat203 Oct 17, 2014 1:45 PM
    dinepat203 dinepat203 Oct 20, 2014 1:09 PM Flag

    We also know that Thomas Eric Duncan, the Liberian man who was the first person to be diagnosed with Ebola on U.S. soil, and Ashoka Mukpo, the NBC cameraman flown back to Nebraska for treatment, received Chimerix's experimental antiviral drug brincidofovir. Mukpo is said to be recovering; Duncan passed away Oct. 8.
    Read MoreWhy we haven't cured Ebola yet

    It's important to remember that none of these drugs were used in controlled clinical trial settings for Ebola, and it's difficult to take anything away about their efficacy, or lack thereof, from these circumstances. Each patient had a unique experience, also received supportive care and in some cases, received donated blood from Ebola survivors.
    So too, will the experiences of the three other patients, whose treatment hasn't been disclosed, be unique.

  • Reply to

    Im about to sell OREXIGEN

    by briannahung0ho Oct 20, 2014 12:09 PM
    dinepat203 dinepat203 Oct 20, 2014 12:25 PM Flag

    price goes up after you sell

  • dinepat203 dinepat203 Oct 20, 2014 10:34 AM Flag

    24 OCTOBER 2014

  • Reply to

    FDA go ahead ?

    by dinepat203 Oct 20, 2014 10:08 AM
    dinepat203 dinepat203 Oct 20, 2014 10:27 AM Flag

    Seeing some activity in hepatitis C, an RNA virus, prompted BioCryst scientists to pursue tests of BCX4430 against other RNA viruses. That’s what led the company to filoviruses, the family of viruses that cause viral hemorrhagic fevers. Both Ebola and Marburg are filoviruses.

  • dinepat203 by dinepat203 Oct 20, 2014 10:08 AM Flag

    $BCRX Favipiravir is the japanese antivaral drug which may had helped the ebola pacient in spain. similar product has BCRX!

  • Reply to

    HAE - $$$$$

    by david_not_a_doc64 Oct 20, 2014 8:58 AM
    dinepat203 dinepat203 Oct 20, 2014 9:49 AM Flag

    National Institute of Allergy and Infectious Diseases (NIAID) has exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2.0 million increase to the existing development contract.

  • dinepat203 dinepat203 Oct 17, 2014 4:07 PM Flag

    What happened to 2 Patients clinical trial (2006) on DMD ?

  • Reply to

    3.47 high of day coming

    by chimewire Oct 17, 2014 3:37 PM
    dinepat203 dinepat203 Oct 17, 2014 3:57 PM Flag

    This is pure fraud company

  • Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
    Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever. Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1). Licensed therapeutic or vaccine products are not available to treat filovirus diseases. Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential. Here we show that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Biochemical, reporter-based and primer-extension assays indicate that BCX4430 inhibits viral RNA polymerase function, acting as a non-obligate RNA chain terminator. Post-exposure intramuscular administration of BCX4430 protects against Ebola virus and Marburg virus disease in rodent models. Most importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when administered as late as 48 hours after infection. In addition, BCX4430 exhibits broad-spectrum antiviral activity against numerous viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. This is the first report, to our knowledge, of non-human primate protection from filovirus disease by a synthetic drug-like small molecule. We provide additional pharmacological characterizations supporting the potential development of BCX4430 as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats.
    Travis K. Warren, Jay Wells, Rekha G. Panchal, Kelly S. Stuthman, Nicole L. Garza, Sean A. Van Tongeren, Lian #$%$, Cary J. Retterer, Brett P. Eaton, Gianluca Pegoraro, Shelley Honnold, Shanta Bantia, Pravin Kotian, Xilin Chen, Brian R. Taubenheim, Lisa S. Welch, Dena M. Minning, Yarlagadda S. Babu

  • dinepat203 dinepat203 Oct 17, 2014 2:06 PM Flag

    I like this article as this has TRUE information and not according to situation like todays date. If this article was published yesterday BCRX would have been $50.

  • Reply to

    EMA on 24th October is 100%

    by dinepat203 Oct 17, 2014 1:33 PM
    dinepat203 dinepat203 Oct 17, 2014 2:04 PM Flag

    Do you read properly ? Approval and Feedback makes sense for you?

  • dinepat203 dinepat203 Oct 17, 2014 1:53 PM Flag

    GSK is out because they are approaching BCRX.....It works.

  • dinepat203 dinepat203 Oct 17, 2014 1:51 PM Flag

    But where???????????? Yesterday or Day before ....? LOL

  • In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack.

    BCX4430, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, is being developed as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BCRX for the development of BCX4430 as a treatment for Marburg virus disease. In 2013, NIAID awarded funding of $7.5 million to BCRX, and total funding of up to $22.0 million, if all contract options are exercised. The goals of this contract are to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.

  • Orexigen did obtain positive feedback from the EMA about Contrave in February this year.

  • dinepat203 dinepat203 Oct 17, 2014 1:29 PM Flag

    Developed by BCRX, BCX4430 has demonstrated antiviral activity in testing conducted at BCRX Utah State University/NIAID and USAMRIID. BCX4430 has been shown to be active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

    In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack.

    BCX4430, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, is being developed as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BCRX for the development of BCX4430 as a treatment for Marburg virus disease. In 2013, NIAID awarded funding of $7.5 million to BCRX, and total funding of up to $22.0 million, if all contract options are exercised. The goals of this contract are to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.

  • Developed by BCRX, BCX4430 has demonstrated antiviral activity in testing conducted at BCRX Utah State University/NIAID and USAMRIID. BCX4430 has been shown to be active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

    In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack.

    BCX4430, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, is being developed as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BCRX for the development of BCX4430 as a treatment for Marburg virus disease. In 2013, NIAID awarded funding of $7.5 million to BCRX, and total funding of up to $22.0 million, if all contract options are exercised. The goals of this contract are to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.

  • Reply to

    SRPT Fraud PR.....BS

    by dinepat203 Oct 17, 2014 12:50 PM
    dinepat203 dinepat203 Oct 17, 2014 1:20 PM Flag

    But Where ???????????

  • dinepat203 dinepat203 Oct 17, 2014 12:53 PM Flag

    Black Gold Knocks

AMGN
162.18+0.60(+0.37%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.